Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TD-0714 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| TD-0714 | EXPERIMENTAL | Capsule formulation |
| Placebo | PLACEBO_COMPARATOR | Capsule formulation |
| Name | Type | Description |
|---|---|---|
| TD-0714 | DRUG | - |
| Placebo | DRUG | - |
| Placebo Comparator | DRUG | One time dosing in capsule formulation |
Inclusion Criteria: * Body Mass Index (BMI) 18 to 32 kg/m2 inclusive * Women of child bearing potential must have a negative pregnancy test and either abstain from sex or use highly effective methods of birth control * Women of non-childbearing potential are at least 2 years postmenopausal or are s...
TD-0714 is an investigational small molecule developed by Theravance Biopharma, Inc. (ticker TBPH). It is a Phase 1 candidate that has been studied in healthy adult and elderly volunteers. The specific therapeutic indication for TD-0714 has not been disclosed.
TD-0714 targets neprilysin (NEP), an enzyme. By acting on this enzyme target, TD-0714 is designed as a small molecule therapeutic. The compound is being developed by Theravance Biopharma as part of its research pipeline.
TD-0714 is being developed by Theravance Biopharma, Inc., which trades under the ticker TBPH. The company is the sponsor of the clinical studies conducted for this asset.
TD-0714 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. Two Phase 1 trials have been completed, and no active trials are currently listed.
TD-0714 has been evaluated in two completed Phase 1 trials. NCT02639078 was a single ascending dose study in 56 healthy subjects, and NCT02709928 was a multiple ascending dose study in 50 healthy and elderly subjects. Both were conducted in the United States.
Both TD-0714 trials were randomized, double-blind, and placebo-controlled Phase 1 studies in healthy volunteers. NCT02639078 enrolled 56 subjects for single ascending doses, while NCT02709928 enrolled 50 healthy and elderly subjects for multiple ascending doses. Total enrollment across the two studies was 106 participants.